Abstract
Presentation of the case
A 56 years old female patient has a history of systemic lupus erythematosus (S.L.E.) and COPD. Symptoms began around prior and gradually improved as she continued to get medications. She has been experiencing Coughing, sputum production, palpitations, chest pain, and wheezing. She describes new-onset and shortness of breathe, labored breathing at rest, mild weariness, feeling chilly and depressed. There are no documented allergies to foods, medications, or the environment.
Her medication includes Hizentra 15 grams, Benlysta 200mg weekly, prednisone 15mg, Amitiza 60x2, Cymbalta 60x2, Topiramate 50 x 2 and 100x2 Fosamax 70 mg week, Botos 200 Units (S.L.E. migraines) Singular 10, Allegra 180, Wellbutrin 300, and Pilocarpine 5x4 and took most medicines of them was taken every week.
Past medical history is significant in developing coronary artery disease, COPD, hypertension, hypothyroidism, myocardial infarction, hyperlipidemia, diabetes mellitus, peripheral vascular disease, and cigarette use. A history of heart catheterization, appendectomy, stent nephrectomy, implantation, hysterectomy, or is noteworthy.
References
- Air pollution and chronic obstructive pulmonary disease. Chronic Diseases and Translational Medicine (2020).
- Akyil FT., et al. “Lifestyle Changes and Exacerbation Frequency of COPD in Times of the Pandemic”. Europe P.M.C (2021).
- Aliagas E., et al. “Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD”. Respiratory Research 19.1 (2018).
- Alqahtani JS., et al. “Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Chronic Obstructive Pulmonary Disease (COPD) 16 Review and Meta-Analysis”. PLOS ONE 15.5 (2020): e0233147.
- Brandl M., et al. “Factors associated with generic health-related quality of life (HRQOL) in patients with chronic obstructive pulmonary disease (COPD): a cross-sectional study”. Journal of Thoracic Disease 10.2 (2018): 766-775.
- Brightling C and Greening N. “Airway inflammation in COPD: progress to precision medicine”. European Respiratory Journal 54.2 (2019): 1900651.
- Crooks MG, Brown T and Morice AH. “Is cough important in acute exacerbations of COPD?”. Respiratory Physiology & Neurobiology 257 (2018): 30-35.
- Delcroix M., et al. “ERS Statement on Chronic Thromboembolic Pulmonary Hypertension”. European Respiratory Journal (2020): 2002828.
- Doiron D., et al. “Air pollution, lung function and COPD: results from the population-based U.K. Biobank study”. European Respiratory Journal 54.1 (2019): 1802140.
- Elhakim TS., et al. “Spontaneous pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19 pneumonia: a rare case and literature review”. B.M.J. Case Reports 13.12 (2020): e239489.
- George PM., et al. “Lung transplantation for idiopathic pulmonary fibrosis”. The Lancet Respiratory Medicine 7.3 (2019): 271-282.
- Guillien A., et al. “COPD, airflow limitation and chronic bronchitis in farmers: a systematic review and meta-analysis”. Occupational and Environmental Medicine 76.1 (2019): 58-68.
- Lázár Z., et al. “Impact of Clinical Factors on Generic and Disease-Specific Quality of Life in COPD and Asthma-COPD Overlap with Exacerbations”. Pulmonary Medicine (2020): e6164343.
- Mosallanezhad Z., et al. Mosallanezhad et al. “The Effects of Vitamin C in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review of Clinical Trials COPD Vitamin C Ascorbic acid”. Int J Nutr Sci 4.4 (2019).
- Rabe KF, Hurst JR and Suissa S. “Cardiovascular disease and COPD: dangerous liaisons?”. European Respiratory Review 27.149 (2018): 180057.
- Stolbrink M, Amiry J and Blakey JD. “Does antibiotic treatment duration affect the outcomes of exacerbations of asthma and COPD? A systematic review”. Chronic Respiratory Disease 15.3 (2017): 225-240.
- Ferguson GT. “Goals of COPD treatment: Focus on symptoms and exacerbations”. Respiratory Medicine 166.1 (2020): 105938.